Merck (NYSE: MRK) is hungrily looking to take a bite out of the weight-loss drugs market. Merck on Dec. 16 said it had just ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Biopharma stocks gained 9.6% in 2024, trailing the S&P 500’s 28.5% rise. Eli Lilly projects double-digit revenue growth ...

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, ...

BMO Capital downgraded Merck (MRK) to Market Perform from Outperform with a price target of $105, down from $136. The firm cites Merck’s ...